Regeneron Pharmaceuticals
The Associate Director leads companion diagnostic strategy and development, bridging translational science with diagnostic execution from early biomarker feasibility through clinical validation and launch. This role involves defining assay intent, designing biomarker strategies, and managing global regulatory submissions to ensure diagnostics align with therapeutic milestones. The position requires translating complex scientific data into validated assays that support drug development decisions.
Headquarters
Tarrytown, New York, United States
Company Size
10001+ employees
Founded
1988
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago
Senior Manager, Biomarker Development
Tango Therapeutics
Director, Regulatory Affairs Companion Diagnostics
Revolution Medicines
Director of Translational Sciences
Century Therapeutics
Sr. Scientist I/II - Pathology Assay Development
MacroGenics
Scientific Advisor, Director
IQVIA
Senior Director, Biomarker Development, Strategy, and Operations
Zenas BioPharma